Department of Microbiology and Immunology, The Medical College of Wisconsin, Milwaukee, Wisconsin, USA
mBio. 2017 Dec 12;8(6):e02087-17. doi: 10.1128/mBio.02087-17.
Although classically associated with myelopoiesis, granulocyte-macrophage colony-stimulating factor (GM-CSF) is increasingly recognized as being important for tuberculosis (TB) resistance. GM-CSF is expressed by nonhematopoietic and hematopoietic lineages following infection with and is necessary to restrict growth in experimental models. Until the recent study by Rothchild et al. (mBio 8:e01514-17, 2017, https://doi.org/10.1128/mBio.01514-17), it was unknown whether GM-CSF-producing T cells contribute to TB resistance. Rothchild et al. identify which conventional and nonconventional T cell subsets produce GM-CSF during experimental TB, establish their protective nature using a variety of approaches, and provide a mechanistic basis for their ability to restrict growth. This commentary discusses the significance of these findings to basic and applied TB research. As translated to human disease, these findings suggest vaccine-mediated expansion of GM-CSF-producing T cells could be an effective prophylactic or therapeutic TB strategy.
虽然粒细胞-巨噬细胞集落刺激因子(GM-CSF)通常与髓系细胞生成有关,但它在结核分枝杆菌(TB)抵抗中的作用正越来越受到关注。感染后,非造血和造血谱系都会表达 GM-CSF,并且在实验模型中限制生长是必需的。直到最近 Rothchild 等人的研究(mBio 8:e01514-17, 2017, https://doi.org/10.1128/mBio.01514-17),人们还不知道产生 GM-CSF 的 T 细胞是否有助于 TB 抵抗。Rothchild 等人确定了在实验性 TB 期间哪些常规和非常规 T 细胞亚群产生 GM-CSF,并用多种方法确定了它们的保护性质,并为它们限制生长的能力提供了机制基础。这篇评论讨论了这些发现对基础和应用 TB 研究的意义。就人类疾病而言,这些发现表明疫苗介导的 GM-CSF 产生 T 细胞的扩增可能是一种有效的预防性或治疗性 TB 策略。